Drug Trial Radar · NCT02745392
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
Last checked: Nov 20, 2026Latest source record: Mar 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
365
Actual
Start
Jun 2016
Primary completion
Jan 2017
Study completion Jan 2017
Sponsor
- Lead sponsor
- Zosano Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Apr 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
Conditions
- Acute Migraine
Interventions
ZP-ZolmitriptanDrug
ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
PlaceboDrug
Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects With Pain FreedomTime frame: 2 hours
- Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)Time frame: 2 hours
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Advantage, Inc./Thunderbird Internal Medicine
Glendale, Arizona
The Research Center of Southern California
Carlsbad, California
Allergy and Asthma Specialists Medical Group and Research Center
Huntington Beach, California
Downtown LA Research Center
Los Angeles, California
Allergy & Asthma Associates of Southern California
Mission Viejo, California
Allergy and Asthma Associates of Santa Clara Valley Research Center
San Jose, California
California Medical Clinic for Headache
Santa Monica, California
Empire Clinical Research
Upland, California
Colorado Allergy & AsthmaCenters, PC
Denver, Colorado
Ki Health Partners
Stamford, Connecticut
Avail Clinical Research, LLC
DeLand, Florida
Medical Research Group of Central Florida
Orange City, Florida
Meridien Research
Tampa, Florida
Clinical Research Atlanta
Stockbridge, Georgia
Boston Clinical Trials
Boston, Massachusetts
Novex Medical Research
New Bedford, Massachusetts
Northeast Medical Research Associates, Inc.
North Dartmouth, Massachusetts
MedVadis Research Corporation
Watertown, Massachusetts
Michigan Head Pain &Neurological Institute
Ann Arbor, Michigan
Westside Family Medical Center, P.C
Kalamazoo, Michigan
Clinical Research Institute, Inc.
Minneapolis, Minnesota
Clinvest/A Division of Banyan Group Inc.
Springfield, Missouri
The Clinical Research Center, LLC
St Louis, Missouri
Nebraska Medical Research Institute
Bellevue, Nebraska
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Princeton Center for Clinical Research
Skillman, New Jersey
Headache Wellness Center, PC
Greensboro, North Carolina
Peters Medical Research LLC
High Point, North Carolina
North Carolina Clinical Research
Raleigh, North Carolina
PMG Research of Raleigh
Raleigh, North Carolina
CTI Clinical Research Center
Cincinnati, Ohio
Coastal Carolina Research Center
Mt. Pleasant, South Carolina
Nashville Neurosciences Group
Nashville, Tennessee
Central Texas Health Research
New Braunfels, Texas
Sylvana Research Associates
San Antonio, Texas
Charlottesville Medical Research Center LLC
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.